BioSpace News Archive

SAB Biotherapeutics announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

Zimmer Biomet Holdings, Inc., a global medical technology leader, published its 2023 Sustainability Report which provides an overview of the company’s environmental, social and governance program, progress, and accomplishments.

Plus Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to raise up to approximately $18 million in gross proceeds, including initial upfront funding of approximately $6.5 million, and up to an additional approximately $11.5 million upon cash exercise of accompanying warrants at the election of the investors.

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its stockholders’ equity is significantly above the $2.5 million minimum required by Nasdaq Listing Rule 5550.

Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.

Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

Krystal Biotech, Inc. today reported financial results and key business updates for the first quarter ending March 31, 2024.

Rhythm Pharmaceuticals, Inc. today announced that the Company delivered three presentations – one oral and two posters – at The Pediatric Endocrine Society’s (PES) Annual Meeting held May 2-5, 2024 in Chicago, IL.

Mineralys Therapeutics, Inc. today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.

BioAtla, Inc. announced that the U.S. Food and Drug Administration has cleared its investigational new drug application to evaluate BA3361 antibody drug conjugate for the treatment of multiple tumor types.